IMDNA provides scientific, technical, and non-regulatory consulting support for molecular biology, biomarker research, immunology, oncology, infectious disease, transplantation, neuroscience, cardiovascular research, cell-based assays, flow cytometry, qPCR/RT-qPCR, ELISA, multiplex immunoassays, lateral-flow development, and translational research programs.
Strong experimental design begins with a clearly defined scientific question and connects that question to appropriate models, controls, endpoints, experimental units, biological and technical replication, randomization or blocking where appropriate, blinding/masking where feasible, sample-size justification, assay performance, predefined analysis, transparent reporting, and independent confirmation. IMDNA helps research teams organize these elements into a coherent plan before resources are committed to experimentation.
NIH defines scientific rigor as the strict application of the scientific method to ensure robust and unbiased experimental design, methodology, analysis, interpretation, and reporting. NIH guidance emphasizes transparency, consideration of relevant biological variables, authentication of key resources, appropriate controls, and explicit plans to address weaknesses in prior evidence.
Define what biological relationship, mechanism, treatment effect, biomarker behavior, assay property, or technical hypothesis the study is intended to test.
Select the sample, cell model, tissue, cohort, assay system, comparator, or experimental platform that can actually answer the question being asked.
Identify primary, secondary, exploratory, and technical endpoints before analysis wherever practical to reduce interpretive flexibility.
Define data processing, normalization, statistical comparisons, exclusions, missing-data handling, and visualization principles before reviewing study outcomes.
NIH, NINDS, NIGMS, and NC3Rs repeatedly emphasize randomization, blinding/masking, sample-size planning, biological and technical replication, transparent exclusion criteria, appropriate controls, and complete reporting as central tools for reducing bias and improving reproducibility.
Define what constitutes an independent biological unit. Multiple wells, technical PCR replicates, or repeated measurements from the same subject do not automatically create independent biological replicates.
Use negative, positive, vehicle, baseline, process, assay, biological, reference, or comparator controls appropriate to the experimental question.
Allocate samples, treatments, plate positions, processing order, or other relevant factors randomly where practical to reduce systematic bias.
Mask treatment/group identity during measurement, gating, scoring, image analysis, or outcome assessment when feasible and scientifically appropriate.
Control known sources of variability—such as batch, sex, instrument, donor, plate, day, or site—through balanced design when appropriate.
Use independent biological units to estimate biological variability and support inference beyond a single specimen, culture, animal, or donor.
Use repeated measurements to understand assay precision without incorrectly treating technical repeats as independent biological observations.
Use effect size, variability, desired precision, statistical power, feasibility, and study design to justify sample number rather than relying only on convention.
Define criteria before analysis where possible and document missing or excluded data transparently.
Consider variables such as sex, age, disease state, donor background, treatment history, cell state, tissue composition, or other context relevant to the biology.
Plan against confounding caused by plate, extraction batch, operator, reagent lot, instrument, sequencing run, staining day, or processing order.
Where the scientific claim requires stronger evidence, confirm important findings in independent samples, cohorts, assays, models, or orthogonal platforms.
IMDNA can help move a project from a broad scientific idea to an experimentally testable and analytically interpretable study plan.
One of the most common experimental-design errors is confusing repeated measurements with independent replication. The experimental unit is the smallest independent unit that can receive a treatment or independently represent the biological comparison. Correct identification of that unit determines the true sample size for statistical inference.
| Example | Independent Biological Units | Technical / Repeated Measurements |
|---|---|---|
| RT-qPCR Study | Independent subjects, animals, tissue specimens, cell preparations, or biological cultures. | Duplicate/triplicate PCR wells from the same cDNA preparation. |
| ELISA | Independent serum/plasma samples, donors, animals, or culture preparations. | Duplicate ELISA wells from the same sample. |
| Flow Cytometry | Independent subjects, donors, cultures, or biological samples. | Repeated acquisitions or aliquots from the same sample unless independently manipulated for a justified reason. |
| Cell-Based Assay | Independent cell preparations, biological experiments, donors, or independently established cultures as appropriate. | Multiple wells from one plating or one culture preparation. |
| Multiplex Immunoassay | Independent study samples or biological preparations. | Duplicate wells or repeated bead measurements from the same sample. |
A control is useful only if it helps distinguish between plausible explanations for the observed result. The correct control strategy depends on the biological system and analytical technology.
Define the expected background or untreated state and help identify nonspecific assay response.
Demonstrate that the biological pathway, assay chemistry, instrument, or analytical workflow can generate the expected response.
Separate the effect of treatment solvent or delivery conditions from the active intervention.
Monitor extraction, reverse transcription, staining, sample preparation, amplification, or another workflow step that could otherwise produce a false negative or technical artifact.
Use a different measurement principle when needed to strengthen evidence that an observed result reflects the intended biology.
Anchor results to an established assay, qualified material, reference lot, standard treatment, benchmark condition, or independent method where appropriate.
NC3Rs and NIH resources emphasize that sample size should be justified rather than selected arbitrarily. Statistical power depends on the expected effect size, variability, alpha level, analysis method, study structure, attrition, multiplicity, and desired probability of detecting a real effect. In some exploratory or analytical studies, precision or confidence-interval width may be more informative than a conventional power calculation.
Small pilot studies can help estimate assay feasibility, event rates, variability, sample handling, and likely effect magnitude. However, variance estimates from very small pilot datasets can be unstable. IMDNA can help separate feasibility objectives from confirmatory statistical objectives when designing pilot work.
NINDS guidance explicitly recommends planned treatment randomization or stratification, masking of outcome assessment where possible, predefined exclusion criteria, reporting of missing data, and reporting of positive and null results. These practices are relevant beyond animal studies whenever group knowledge, run order, plate position, analyst decisions, or sample handling could systematically influence an outcome.
When feasible, avoid predictable assignment patterns that could align treatment with day, operator, plate, cage, instrument, or other confounding factors.
Distribute experimental groups across extraction batches, PCR plates, ELISA plates, staining runs, acquisition order, or other technical batches.
Where subjective gating, image analysis, pathology scoring, manual classification, or interpretation is involved, consider masking group identity.
Use stratification or block randomization when a known biological or technical variable could otherwise become confounded with treatment.
If blinding or randomization is impossible, document why and consider alternative strategies that reduce bias.
Define transformations, gates, exclusions, thresholds, normalization, and statistical models before unmasking outcomes where practical.
IMDNA can help decide whether a project is best answered using gene expression, protein measurement, cellular phenotype, functional response, rapid POC technology, or an integrated multi-platform approach.
| Scientific Question | Potential Technology | What the Technology Adds |
|---|---|---|
| Is a transcript changing? | RT-qPCR / multiplex RT-qPCR | Focused transcript quantification, pathway profiling, biomarker-expression research. |
| Is a soluble protein changing? | ELISA / multiplex bead-based immunoassay | Protein-level biomarker concentration and multi-analyte immune profiling. |
| Which cells are changing? | Flow cytometry / immunophenotyping | Cell-subset abundance, phenotype, activation, differentiation, and single-cell readouts. |
| Are the cells functionally different? | Cell-based / functional assays | Viability, signaling, proliferation, cytotoxicity, cytokine response, target engagement, or phenotypic function. |
| Can the result be translated to a rapid format? | POC / lateral flow development | Portable qualitative, semi-quantitative, or reader-assisted test concepts. |
| Is the biology multi-layered? | Integrated molecular + protein + cellular strategy | Combines transcript, protein, phenotype, and functional evidence for stronger mechanistic interpretation. |
The NIH/NCATS Assay Guidance Manual emphasizes robust assay development, appropriate statistical analysis, and optimization that allows the assay to tolerate minor protocol variation. IMDNA can incorporate these principles when designing qPCR, immunoassay, cell-based, flow-cytometry, or other research assays.
Determine whether the assay can distinguish biologically meaningful conditions from background or negative controls.
Define the region over which the assay produces interpretable and reproducible measurements.
Characterize technical variation to understand how much of the observed difference can be attributed to measurement noise.
Determine whether the measurement reflects the intended target, phenotype, pathway, or biological response.
Test realistic changes in operator, timing, temperature, reagent concentration, lot, instrument, sample handling, or plate position.
Evaluate whether serum, plasma, tissue, cells, extraction buffer, or other matrix components alter the assay response.
Use controls that demonstrate both biological response and analytical performance.
Identify likely sources of false signal, loss of sensitivity, drift, contamination, assay saturation, or biological instability before scaling the study.
A small p-value does not by itself establish biological relevance, reproducibility, causality, biomarker validity, predictive value, or translational utility. IMDNA encourages interpretation that considers effect size, uncertainty, biological plausibility, assay quality, multiplicity, study design, technical limitations, replication, and independent evidence alongside statistical significance.
NINDS recommends reporting sample size, effect size, uncertainty, missing data, exclusions, and all outcomes, while NIH emphasizes transparent methods and reproducibility. Analysis planning should therefore begin during study design rather than after data collection.
Define the main experimental comparison or model that directly addresses the primary hypothesis.
Consider whether the data structure supports parametric, nonparametric, count, binary, survival, repeated-measures, mixed-effects, or other models.
Account for within-subject or within-donor correlation rather than treating longitudinal measurements as independent samples.
Plan how multiplicity will be handled when testing many biomarkers, timepoints, cell populations, genes, or hypotheses.
Define handling rules transparently and distinguish technical failure, biological exclusion, attrition, and missing measurement.
Report estimates and confidence intervals or other uncertainty measures where appropriate, not only hypothesis-test p-values.
Evaluate published evidence, biomarker rationale, biological mechanisms, assay precedent, and technical limitations.
Translate a broad scientific idea into testable primary and secondary hypotheses.
Select candidate genes, proteins, cell populations, pathways, or functional endpoints based on study objectives.
Choose qPCR/RT-qPCR, ELISA, multiplex bead assays, flow cytometry, cell-based methods, POC formats, or combinations based on the question.
Define controls, experimental units, groups, timepoints, replication, randomization, blinding, sample size, and batch structure.
Plan feasibility, optimization, analytical performance, controls, matrix evaluation, robustness, and technical transfer.
Connect assay QC, effect size, statistical analysis, biological context, and limitations to scientifically defensible conclusions.
Investigate failed experiments, high variability, weak signal, conflicting platforms, batch effects, or unexpected biology and revise the design accordingly.
Support scientific rationale, assay strategy, experimental logic, feasibility, milestones, biomarker plans, and technical methods sections.
Help organize methods, figures, result interpretation, limitations, experimental transparency, and technical discussion.
Document the experimental rationale, controls, workflows, assay settings, analysis rules, and troubleshooting knowledge needed for another team or site.
Identify what additional evidence may be required to move an exploratory biomarker or research assay toward stronger validation or product development.
IMDNA provides scientific, technical, experimental-design, biomarker-strategy, assay-development, data-interpretation, troubleshooting, documentation, and non-regulatory consulting support based on the needs of each research project. Support may include literature review, hypothesis development, model selection, controls, experimental units, biological/technical replication, randomization/blinding strategies, sample-size planning, assay selection, biomarker selection, analytical-performance planning, statistical-analysis planning, result interpretation, technical reporting, and technology transfer.
Experimental design is project specific. Randomization, masking, sample-size calculations, statistical models, replication strategies, controls, and validation requirements should be selected according to the actual scientific question, model, endpoint, study phase, and intended use. Guidance developed for animal, clinical, regulatory, or drug-development research should not be automatically applied outside its stated scope.
IMDNA is not a regulatory, legal, biostatistical certification, accreditation, governmental, ethics-review, or institutional-review authority. Where specialized biostatistical, clinical, legal, regulatory, animal-welfare, institutional-review, or other formal expertise is required, the responsible organization should engage appropriately qualified professionals and authorized review bodies.
IMDNA scientific consulting does not guarantee that an experiment will produce a positive result or that a biomarker, assay, hypothesis, intervention, or product will be validated, publishable, clinically useful, fundable, regulatorily accepted, or commercially successful.
References to NIH, NINDS, NIGMS, NCATS, NC3Rs, or other organizations are provided as scientific and educational frameworks only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA.
The following resources support the scientific framework used on this page. Their scope differs, so they should be applied according to the actual research context.
Tell IMDNA about your biological question, existing evidence, experimental model, biomarkers, available samples, technology options, controls, groups, timepoints, expected effect, data type, and translational objective. Our scientific team can help organize an experimental-design and consulting strategy covering literature review, hypothesis development, biomarker and assay selection, controls, replication, randomization/blinding concepts, sample-size planning, analytical strategy, QC, data interpretation, troubleshooting, documentation, and technology transfer.